Vetted by NeuralPress's Multi-Agent Verifier for strict factual validity and event relevance. Our compliance engine cross-checks and filters search results to ensure zero false correlations or misleading content.
Sectoral Growth due to GLP-1 Trend
Estimated impact areas for consumers on GLP-1 medications
Primary Sources
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
As you were browsing something about your browser made us think you were a bot. There are a few reasons this might happen: You're a power user moving through this website with super-human speed. You've disabled cookies in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing JavaScript from running. Additional information is available in this support article. To regain access, please make sure that cookies and JavaScript are enabled before reloading the page.
These patients without drug coverage are eagerly awaiting generic ...
Anne Welch worked a physically demanding job at her local SPCA — lifting pets, cleaning kennels and walking dogs — until she retired at age 71 TORONTO — Anne Welch worked a physically demanding job at her local SPCA — lifting pets, cleaning kennels and walking dogs — until she retired at age 71. With the loss of that physical activity, coupled with an underactive thyroid, "the weight just started piling on," the now-77 year old said in an interview from her home in Paris, Ont. "(I'm) definitely feeling very down at times because I try so hard and I'll go for a few weeks and I won't eat any sweets and I'll try to eat salads and then all of the sudden I wake up one morning and all I can think about is eating sweets," Welch said. "I'm sure that my back issues and my other issues would be helped by me being able to lose weight," she said. Welch asked her doctor if Ozempic was an option. She said her doctor told her that the GLP-1 medication would be helpful and "she was more than happy to prescribe it for me." But because Welch doesn't have diabetes, the Health Canada approved condition for which Ozempic is prescribed, the Ontario Drug Benefit program that covers medications for seniors 65 and older doesn't fund it. That's in line with public drug plans across the country, according to the Canadian Institute for Health Information (CIHI). Living on a fixed income of the Canada Pension Plan and Old Age Security, Welch said she can't afford to pay for the drug — which often costs a few hundred dollars a month — out of pocket. It's "very frustrating," she said, because she's watched her husband Steve lose 30 to 40 pounds on Ozempic and keep it off. He got coverage from the provincial drug program because he has a diagnosis of diabetes. Welch is hoping that one of the nine generic semaglutide drugs — the active ingredient in Ozempic — currently under review by Health Canada will soon be approved. Generic semaglutide would be cheaper than brand-name Ozempic, but how much depends on how many generic options are approved and hit the market, said Mina Tadrous, a pharmaceutical policy expert at the University of Toronto. According to the pricing structure of the pan-Canadian Pharmaceutical Alliance, the first generic medication could cost 75 to 85 per cent of the brand name. Once a second medication enters the market, the price for both drops to 50 per cent. When there are three or more generic products available in Canada, the cost would decrease to about...
Weight-loss treatment may soon require far fewer injections—but it's ...
No weekly injections needed. In a groundbreaking leap beyond weekly injections, scientists say they've developed a way to reprogram the body to produce its own ...
Eli Lilly's weight loss drug Mounjaro (tirzepatide) continued to rank ...
Eli Lilly's weight loss drug Mounjaro (tirzepatide) continued to rank as India's top pharmaceutical brand in March 2026. Still, the tirzepatide blockbuster ...
